Latest in News & Research
Age, Comorbidity Score Prognostic for Skin Appendage Carcinoma
Better survival predicted with private insurance compared with Medicaid, Medicare, no insurance
Deep Learning Model Developed for Classification of Melasma Severity
Area under the curve values reached 0.93, 0.86, and 0.94 for mild, moderate, and severe melasma with GoogLeNet model
Global Burden of Atopic Dermatitis in Older Adults Is Considerable
Global prevalence of older adult AD increased from 1990 to 2021 and is expected to continue increasing to 2050
Mutation Burden in Normal Skin Increases With Narrow-Band UVB in Psoriasis
Point at which skin cancer surveillance should be offered estimated based on NB-UVB exposure, sun exposure
AACR: Pretrained Machine Learning Models Help Diagnose Nonmelanoma Skin Cancer
Leveraging whole slide embeddings from pretrained machine learning models can improve diagnosis of nonmelanoma skin cancer
FDA Approves Zevaskyn for Rare, Genetic Skin Disorder
Zevaskyn is the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa
Psoriatic Arthritis Tied to Delays in Diagnosis Compared With Rheumatoid Arthritis
Patients with psoriatic arthritis are less likely to begin disease-modifying antirheumatic drug therapy
Adult Acne Linked to Higher Risk for Eating Disorders
Findings attenuated but still significant after allowing for history of anxiety, depression, body dysmorphic disorder
Risk for Secondary Cancer Higher for Primary Cutaneous B-Cell Lymphoma
Patients with pCBCL have increased risk for second primary prostate cancer and lymphoma
Ivarmacitinib Efficacious for Moderate-to-Severe Atopic Dermatitis
More patients achieved IGA score of 0 or 1 with at least a 2-grade improvement with once-daily 4-mg or 8-mg ivarmacitinib versus placebo
Launch Alert: Dupixent Approved for Chronic Spontaneous Urticaria (CSU)
New FDA approval expands treatment options for chronic spontaneous urticaria patients aged 12 years and older
Early-Onset Pediatric Atopic Dermatitis Tied to Higher Risk for Uveitis
Findings independent of autoimmune conditions or dupilumab use
FDA Approves Dupixent for Chronic Spontaneous Urticaria
Approval granted for adults and children 12 years and older who remain symptomatic despite antihistamine treatment
Imaging Aids Management in High-Risk Cutaneous Squamous Cell Carcinoma
Unexpected imaging findings seen in 49 percent of imaged tumors, resulting in changed management in 47 percent of cases
Rilzabrutinib Beneficial for Treating Chronic Spontaneous Urticaria
Significant reductions seen in end points, including weekly Itch Severity Score, weekly Urticaria Activity Score
Flares Occur Frequently in Generalized Pustular Psoriasis
Frequent treatment alterations of off-label biologics and nonsteroidal systemic agents observed
Circulating Tumor DNA Can ID Outcomes for Patients With Melanoma
ctDNA detection at baseline was associated with worse recurrence-free, overall survival in BRAFV600-mutant stage III melanoma
Melanoma Brain Metastases Risk Reduced With Immune Checkpoint Treatment
Risk for brain metastases development increased in association with elevated plasma levels of S100B, higher metastatic stage
Guidance Provided for Dermatologists Photographing Skin of Color
Royal blue backgrounds preferred for photographing darker skin, offering increased contrast without aberrant hues
Cybersecurity: Checklist for Safety and Preparedness
In this recurring column, Dermsquared and J.P. Morgan provide tailored financial strategies and investment insights for the dermatology community. Each 500-word article highlights key...
Severity of Eyebrow, Eyelash Loss Parallels Scalp Hair Loss in Alopecia Areata
Baricitinib efficacious for achieving holistic response across all three hair-bearing sites
High Quality Images Seen With Autonomous Total Body Photography + Dermoscopic Device
Quality of images produced by autonomous TBP and dermoscopic device comparable to standard dermoscopic techniques
Autologous Cell Harvesting Device Increases Repigmentation in Vitiligo
All lesions demonstrated improvement by week 24, with 42 percent achieving ≥80 percent repigmentation
24 of 1238